Tag Archives: Institute of Medicine

A Weekly Advocacy Message from Mary Woolley: Risky business

Dear Research Advocate:

What does the current political impasse in Washington have in common with deadly or disabling diseases? They will not cure themselves, and the harm escalates until the “patient” gets expert treatment. There is no place for miracle cures or wishful thinking. The solution isn’t what a given individual or party wants it to be, it’s what solves the problem. Right now, it’s by no means clear what or who will solve the problems — which now include the debt ceiling as well as the lack of funding to run the government. Fasten your seat belts for more turbulence between now and October 17th.

You may have heard that the House passed a bill yesterday to fund NIH, along with several other stand-alone appropriation bills (funding it at an unacceptably low level, I might add — below FY12 levels). Beyond the fact that this piecemeal, slow-walking avoidance tactic of finding a solution to the government shutdown is dead on arrival in the Senate and the White House, this “Sophie’s Choice,” cherry-picking approach to better health has no place in a functioning research and innovation ecosystem, and we spoke out against it. That said, it was gratifying that NIH was singled out as publicly popular and good to see the possibility of new champions emerging who recognize the importance of NIH funding during the floor debate on the bill. But make no mistake, had we and other advocates supported this ill-conceived measure, we would have been supporting the decline of science in this nation. Continue reading →

Advertisements

A Weekly Advocacy Message from Mary Woolley: Additions to the Sequestration Files

Dear Research Advocate:

On Wednesday, the House Appropriations agriculture subcommittee approved the funding bill that includes the Food and Drug Administration. The bill allocates nearly $100 million above the post-sequester levels. Unfortunately, the baseline budgets in the House are so low that this increase is still lower than FY12 FDA funding. We must not fall into the trap of lowering our expectations and applauding an artificial victory. The true mark of success is funding that keeps up with need. We must keep working.

As demonstrated particularly by the 18.6% cut targeted for the House LHHS appropriations FY14 budget, the pressure to shrink government by slashing discretionary spending shows no sign of abating. This pressure continues despite the damage nationwide in furloughs, layoffs, shuttered labs, patients turned away from clinical trials, and uncertainty around the ability of federal agencies to accomplish the basic government functions that help sustain an advanced society.

Speaking of mounting evidence against consequence-blind budget cuts, the lab that quickly identified the ricin toxin in letters sent recently to elected officials is CDC-funded. The Spokane (WA) Regional Health District Bioterrorism Lab is threatened with closure due to budget cuts (read more in the Homeland Security News Wire report). Of course it’s not only ricin-laced letters that must be stopped in their tracks. For example: The president has declared an emerging respiratory infection from the Middle East (known as MERS-CoV) a “potential public health emergency.” How can we expect the CDC to be effective in identifying, preventing and combating this or other global threats without the resources needed to do its job? Continue reading →